May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
24-Hour Intraocular Pressure Control Obtained With Evening versus Morning Dosed Travoprost/Timolol Maleate Fixed Combination in Patients With Open-Angle Glaucoma
Author Affiliations & Notes
  • A. G. Konstas
    1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • S. Tsironi
    1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Department of Ophthalmology, Papanikolaou Hospital, Thessaloniki, Greece
  • A. N. Vakalis
    1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • M. B. Nasr
    1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • L. A. Nelson
    Pharmaceutical Research Network, LLC, Charleston, South Carolina
  • W. C. Stewart
    Pharmaceutical Research Network, LLC, Charleston, South Carolina
    University of South Carolina, School of Medicine, Columbia, South Carolina
  • Footnotes
    Commercial Relationships A.G. Konstas, Alcon, F; S. Tsironi, None; A.N. Vakalis, None; M.B. Nasr, None; L.A. Nelson, None; W.C. Stewart, None.
  • Footnotes
    Support The clinical site was supported in part by Alcon, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. G. Konstas, S. Tsironi, A. N. Vakalis, M. B. Nasr, L. A. Nelson, W. C. Stewart; 24-Hour Intraocular Pressure Control Obtained With Evening versus Morning Dosed Travoprost/Timolol Maleate Fixed Combination in Patients With Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5569.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate 24-hour intraocular pressure control between morning and evening dosing of travoprost/timolol maleate fixed combination in patients with open-angle glaucoma.

Methods:: The design was a prospective, randomized, double-masked, active-controlled, crossover comparison. Following a medicine free period, patients were randomized to travoprost/timolol maleate fixed combination dosed in the morning or evening. Following 8 weeks of treatment intraocular pressure was measured at 10 AM, 2 PM, 6 PM, 10 PM, 2 AM and 6 AM. Patients then were treated with the opposite dosing regimen for another 8 weeks and the 24-hour intraocular pressure curve was repeated.

Results:: In 32 completed subjects the untreated mean 24-hour intraocular pressure was 27.7 ± 3.5 mm Hg. Both dosing regimens reduced the intraocular pressure from untreated baseline at each time point and for the 24-hour intraocular pressure curve (P < 0.0001). When treatments were compared directly, evening dosing (18.4 ± 3.3 mm Hg) provided a statistically lower 24-hour curve for the absolute intraocular pressure than morning dosing (19.2 ± 3.5 mm Hg, P = 0.001) as well as for the 10 AM, 2 PM, 6 PM and 6 AM time points (P ≤ 0.03). Evening dosing provided a lower 24-hour intraocular pressure fluctuation (3.8 ± 1.6 mm Hg) compared to morning dosing (5.1 ± 1.6 mm Hg, P = 0.0002) and lower peak intraocular pressure (20.4 ± 3.8 mm Hg) compared to morning dosing (21.7 ± 3.9, P = 0.0003). Safety was similar between groups with conjunctival hyperemia being the most common adverse event (n = 7, 22%) for both regimens (P = 1.0).

Conclusions:: This study suggests that both morning and evening dosing of travoprost/timolol maleate fixed combination provide effective 24-hour intraocular pressure reduction. However, evening dosing demonstrates better quality of 24-hour intraocular pressure control.

Clinical Trial:: www.clinicaltrials.gov NCT00331240

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×